FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2584624967> ?p ?o ?g. }

• W2584624967 endingPage "3543" @default.
• W2584624967 startingPage "3535" @default.
• W2584624967 abstract "Chemotherapy induced nausea and vomiting (CINV) is a side effect, and has negative effect on quality of life and continuation of chemotherapy. Despite new regimen and drugs, the problems still remain and standard guidelines, effective treatment and supportive care for refractory CINV are still not yet established. Persian medicine, the old Iranian medical school, offer Persumac (prepared from Rhus Coriaria and Bunium Persicum Boiss).The specific objectives were to assess the effect of Persumac on the number and severity of nausea and vomiting in refractory CINV in acute and delayed phase.This randomized, double blind, crossover clinical trial study was carried out on 93 patients with breast cancer and refractory CINV, who received outpatient high emetogenic chemotherapy in Imam Reza hospital, Mashhad, Iran from October 2015 to May 2016. The study has three stages: in stage I patients received a questionaire and completed it after chemotherapy. In stage II they were randomly divided into intervention group with Persumac and control group with placebo (lactose were used). In stage III, wash out and crossover was conducted. Both groups in all stages received standard antiemetic therapy for CINV. The following were set as the inclusion criteria of the study: female, Age ≥18 years, clinical diagnosis of breast cancer, history of refractory CINV, normal blood tests and at least three courses of chemotherapy remaining. Exclusion criteria of this study were: Total or upper abdominal radiation therapy along with chemotherapy, drugs/therapy for nausea and vomiting not prescribed in this study, hypersensitivity to Sumac or Bunium Persicum, use of sumac and Bunium Persicum in seven days prior to the intervention, clinical diagnosis of digestion disorders, non-chemotherapy induced nausea and vomiting, milk allergy, loss of two consecutive or three intermittent doses of Persumac or placebo. Outcomes were gathered by Persian questionnaire. Number and severity of nausea and vomiting was measured with a self-reporting tool; visual analog scale.Demographic data and other characters in both groups have no significant diffrence. Eighty of 93 eligible patients in stage I completed the study and in stage II, eleven declined participation for stage III (crossover). P value of carry over, period and treatment effects demonstrated that they had not affected the results before and after crossover. The mean severity of nausea in acute phase was in stage I: 4.83 ± 1.40, stage II: 4.54 ± 2.0 and stage III: 4.15 ± 0.92 in sequence AB (first Persumac and then placebo in crossover), and in sequence BA (first placebo and then Persumac in crossover) was respectively 4.83 ± 1.40, 4.54 ± 2.0, 4.15 ± 0.92 with p value of carry over effect: 0.03 and period effect: 0.22. Except for severity of nausea in acute phase, the mean number and severity of nausea and vomiting scores significantly decreased in acute and delayed phase of CINV.Persumac may control the refractory CINV. The implicable and clinical importance of this research is that another option exists for refractory CINV. Higher doses, different cancers, patients with more various features, and more complete methodology and tools can provide appropriate designs for new research on this topic.This trial was registered at the Clinical Trials.gov ID: NCT02787707.This study is part of a Ph.D. thesis and under grant; No: 930735 of Research Chancellery of MUMS." @default.
• W2584624967 created "2017-02-10" @default.
• W2584624967 creator A5014884850 @default.
• W2584624967 creator A5017311650 @default.
• W2584624967 creator A5031105705 @default.
• W2584624967 creator A5063901170 @default.
• W2584624967 creator A5077105981 @default.
• W2584624967 date "2017-01-25" @default.
• W2584624967 modified "2023-10-04" @default.
• W2584624967 title "Effect of Persian Medicine Remedy on Chemotherapy Induced Nausea and Vomiting in Breast Cancer: A Double Blind, Randomized, Crossover Clinical Trial" @default.
• W2584624967 cites W2043380382 @default.
• W2584624967 cites W2074204571 @default.
• W2584624967 cites W2091757652 @default.
• W2584624967 cites W2132738767 @default.
• W2584624967 cites W2140767828 @default.
• W2584624967 cites W2153848705 @default.
• W2584624967 cites W2167393786 @default.
• W2584624967 cites W2200283932 @default.
• W2584624967 cites W2329900495 @default.
• W2584624967 cites W2463105850 @default.
• W2584624967 cites W767391739 @default.
• W2584624967 doi "https://doi.org/10.19082/3535" @default.
• W2584624967 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5308492" @default.
• W2584624967 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28243404" @default.
• W2584624967 hasPublicationYear "2017" @default.
• W2584624967 type Work @default.
• W2584624967 sameAs 2584624967 @default.
• W2584624967 citedByCount "6" @default.
• W2584624967 countsByYear W25846249672018 @default.
• W2584624967 countsByYear W25846249672021 @default.
• W2584624967 countsByYear W25846249672022 @default.
• W2584624967 countsByYear W25846249672023 @default.
• W2584624967 crossrefType "journal-article" @default.
• W2584624967 hasAuthorship W2584624967A5014884850 @default.
• W2584624967 hasAuthorship W2584624967A5017311650 @default.
• W2584624967 hasAuthorship W2584624967A5031105705 @default.
• W2584624967 hasAuthorship W2584624967A5063901170 @default.
• W2584624967 hasAuthorship W2584624967A5077105981 @default.
• W2584624967 hasBestOaLocation W25846249671 @default.
• W2584624967 hasConcept C121608353 @default.
• W2584624967 hasConcept C126322002 @default.
• W2584624967 hasConcept C168563851 @default.
• W2584624967 hasConcept C2776694085 @default.
• W2584624967 hasConcept C2779924295 @default.
• W2584624967 hasConcept C2780580376 @default.
• W2584624967 hasConcept C2780852908 @default.
• W2584624967 hasConcept C2780884295 @default.
• W2584624967 hasConcept C530470458 @default.
• W2584624967 hasConcept C71924100 @default.
• W2584624967 hasConceptScore W2584624967C121608353 @default.
• W2584624967 hasConceptScore W2584624967C126322002 @default.
• W2584624967 hasConceptScore W2584624967C168563851 @default.
• W2584624967 hasConceptScore W2584624967C2776694085 @default.
• W2584624967 hasConceptScore W2584624967C2779924295 @default.
• W2584624967 hasConceptScore W2584624967C2780580376 @default.
• W2584624967 hasConceptScore W2584624967C2780852908 @default.
• W2584624967 hasConceptScore W2584624967C2780884295 @default.
• W2584624967 hasConceptScore W2584624967C530470458 @default.
• W2584624967 hasConceptScore W2584624967C71924100 @default.
• W2584624967 hasIssue "1" @default.
• W2584624967 hasLocation W25846249671 @default.
• W2584624967 hasLocation W25846249672 @default.
• W2584624967 hasLocation W25846249673 @default.
• W2584624967 hasLocation W25846249674 @default.
• W2584624967 hasOpenAccess W2584624967 @default.
• W2584624967 hasPrimaryLocation W25846249671 @default.
• W2584624967 hasRelatedWork W1557364596 @default.
• W2584624967 hasRelatedWork W1974541163 @default.
• W2584624967 hasRelatedWork W2003697710 @default.
• W2584624967 hasRelatedWork W2033327063 @default.
• W2584624967 hasRelatedWork W2080135046 @default.
• W2584624967 hasRelatedWork W2119857165 @default.
• W2584624967 hasRelatedWork W2385256069 @default.
• W2584624967 hasRelatedWork W2389606934 @default.
• W2584624967 hasRelatedWork W2611083795 @default.
• W2584624967 hasRelatedWork W2972704086 @default.
• W2584624967 hasVolume "9" @default.
• W2584624967 isParatext "false" @default.
• W2584624967 isRetracted "false" @default.
• W2584624967 magId "2584624967" @default.
• W2584624967 workType "article" @default.